Terray Therapeutics Raises $60M in Series A Funding
- Terray Therapeutics, a Pasadena, CA-based biotechnology company, raised $60M in Series A funding
- The company intends to use the funds to advance its preclinical pipeline of therapeutics and its discovery partnerships
- TerrayTherapeutics is a biotechnology company that leverages AI, synthetic chemistry, automation, and nanotechnology to propel drug discovery into the information age
- Terray’s proprietary integrated computational and experimental platforms generate scaled, agnostic chemical data that are purpose-built to power computational learning and reveal new interactions
- This financing follows a previously unannounced $20 million seed round co-led by Digitalis Ventures and Two Sigma Ventures